Not logged in Login 
 Home 
 Managers 
 Funds 
 Charting 
 Ebook 
 Admin   Login  
  Alert me on this fund
  Add fund to active Watchlist
     
Franklin Biotechnology Discovery Fund  |  USA--Equity--Unclassified
68.3600    +0.5100    (+0.752%)
NAV price (USD) Wed 11 Nov 2026 (change prev close)
  
1134.2770    +13.7003    (+1.223%)
NAV price (ZAR) Wed 11 Nov 2026 (change prev close)
 
Snapshot
<i><b>  Performance</b></i><hr/>This gauge shows the decile position of the fund against 22 Rand-denominated Equity-Unclassified funds over the last three years (needle right indicates above average performance)
Performance
<i><b>  Size</b></i><hr/>This gauge shows the size of the fund against all Rand-denominated retail funds (needle right indicates a large fund, needle left a small fund)
Size
<i><b>  Diversification</b></i><hr/>This gauge shows the level of diversification relative to other funds in the same second-tier (equity) category (needle right indicates a well-diversified fund)
Diversification
<i><b>  Risk</b></i><hr/>This gauge shows the fund's level of historical risk relative to other funds in the Equity-Unclassified sectors based on 3-year volatility (needle right indicates lower risk within the sector)
Risk
Fund Performance
  ZAR
  Base
3 Months 6 Months 1 Year 3 Years 5 Years
Trailing Returns
Period    Return %Growth of $1 000
chart
* Not annualised
Key Facts and Fund Objective
Key Facts
Formation Date 3 Apr 2000
Fund Size ($) 1 820 000 000
Latest Price 68.36
PlexCrowns (Senior)
PlexCrowns (Junior)
Total Expense Ratio-
Minimum Investment$5 000
TTM Distribution Yield -
Fund Objective
The investment objective of the fund is capital growth by investing in equity securities of biotechnology companies and discovery research firms mainly located in the USA substantial portion of its assets will be in smaller capitalisation companies (those with market capitalisation of less than USD2bn). For the fund's investment purposes, a biotechnology company is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities based on the company's most recent fiscal year. Biotechnology activities are research, development, manufacture and distribution of various biotechnological or biomedical products, services and processes. This may include companies involved with genomics, genetic engineering and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals and agriculture. To the extent that the fund invests in debt securities, it generally buys securities that are rated investment grade or unrated securities that it determines to be of comparable quality. Investment grade debt securities are rated in the top four ratings categories by independent ratings organisations such as Standard & Poor's Corporation or Moody's Investors Service Inc. The fund anticipates that under normal conditions, it will invest more of its assets in US securities than in those of any other single country although the fund may have more than 50% of its total assets in non-US securities. The manager may take a temporary defensive position when it believes the securities trading markets or the economies of countries where the fund invests are experiencing excessive volatility or prolonged general decline, or other adverse conditions exist. Under these circumstances, the fund may be unable to pursue its investment goal.
Asset Classes and Holdings
Asset Classes as at 30 Jun 2026
 SA Equities0.00%  
 Foreign Equities97.53%  
 SA Bonds0.00%  
 Foreign Bonds0.00%  
 SA Property0.00%  
 Foreign Property0.00%  
 SA Cash0.00%  
 Foreign Cash2.47%  
Top Holdings as at 30 Sep 2026
SecurityValue% of Fund
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY 1 731.5m ZAR5.02%
AMGEN INC. 1 631.4m ZAR4.73%
GILEAD SCIENCES, INC. 1 565.9m ZAR4.54%
VERTEX PHARMACEUTICALS INCORPORATED 1 376.2m ZAR3.99%
ARGENX SE 1 338.3m ZAR3.88%
REGENERON PHARMACEUTICALS INC 1 321.0m ZAR3.83%
REVOLUTION MEDICINES INC 1 165.8m ZAR3.38%
Guardant Health, Inc. 1 041.6m ZAR3.02%
ASTRAZENECA PLC 1 024.4m ZAR2.97%
BridgeBio Pharma, Inc. 872.6m ZAR2.53%
Totals 13 068.8m ZAR37.89%
More Information and Research Tools
Recently viewed
11 Nov68.36+0.51+0.75% 
10 Nov15.170.000.00% 
11 Nov34.64+0.27+0.79% 
Watchlists
Portfolios